On Feb. 12, 2021, CureVac announced initiation of a rolling submission with the European Medicines Agency (EMA) for CVnCoV, the companyﾒs mRNA-based COVID-19 vaccine candidate, currently in late-stage clinical testing. The process was initiated when the first data package consisting of CVnCoV pre-clinical data was submitted to EMA and passed the technical validation.